Trophos initiates clinical development for novel cardioprotective compound, TRO40303
First in human study for innovative approach to reducing cardiac ischemia-reperfusion injury
30-Sep-2010 -
Trophos SA announced the initiation of clinical development for TRO40303, a novel mitochondria pore modulator. TRO40303 could become the first treatment to reduce the cardiac reperfusion injury that contributes significantly to the morbidity and mortality seen post myocardial infarction (MI). The ...
acute myocardial infarction
amyotrophic lateral sclerosis
ischemia reperfusion
+4